Purpureocillium lilacinum as a cause of cavitary pulmonary disease: a new clinical presentation and observations on atypical morphologic characteristics of the isolate.
The first case of cavitary pulmonary disease caused by Purpureocillium lilacinum is described. The isolate showed atypical microscopic characteristics similar to Acremonium and Fusarium spp., which necessitated molecular identification by sequencing of multiple conserved loci. The patient responded to voriconazole, reinforcing its therapeutic efficacy for P. lilacinum infections.
Department of Microbiology, Faculty of Medicine, Kuwait University, Safat, Kuwait. zkhan@hsc.edu.kw
Ziauddin
Z
Khan
Suhail
S
Ahmad
Fahad
F
Al-Ghimlas
Sana
S
Al-Mutairi
Leena
L
Joseph
Rachel
R
Chandy
Deanna A
DA
Sutton
Josep
J
Guarro
D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000008:administration & dosage; D004271:DNA, Fungal / Q000737:chemistry / Q000235:genetics; D005260:Female; D006801:Humans; D006999:Hypocreales / Q000145:classification / Q000166:cytology / Q000302:isolation & purification*; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology*; D008853:Microscopy; D008969:Molecular Sequence Data; D009181:Mycoses / Q000188:drug therapy / Q000382:microbiology* / Q000473:pathology*; D011743:Pyrimidines / Q000008:administration & dosage; D017422:Sequence Analysis, DNA; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage; D065819:Voriconazole
D000935:Antifungal Agents; D004271:DNA, Fungal; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole